These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 16118670)

  • 61. The resurgence of swine-origin influenza A (H1N1).
    Mossad SB
    Cleve Clin J Med; 2009 Jun; 76(6):337-43. PubMed ID: 19487554
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home.
    Iorio AM; Neri M; Lepri E; Camilloni B; Basileo M; Sigismondi N; Fabiani C; Calzoletti L; Puzelli S; Donatelli I
    Vaccine; 2006 Nov; 24(44-46):6615-9. PubMed ID: 16828941
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Influenza type A (H5N1) virus infection].
    Engin A
    Mikrobiyol Bul; 2007 Jul; 41(3):485-94. PubMed ID: 17933264
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Selection bias in evaluating of influenza vaccine effectiveness: a lesson from an observational study of elderly nursing home residents.
    Fukushima W; Hayashi Y; Mizuno Y; Suzuki K; Kase T; Ohfuji S; Fujieda M; Maeda A; Hirota Y
    Vaccine; 2008 Nov; 26(50):6466-9. PubMed ID: 18582520
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Using surveillance to evaluate influenza vaccine effectiveness.
    Jackson LA
    J Infect Dis; 2009 Jan; 199(2):155-8. PubMed ID: 19086916
    [No Abstract]   [Full Text] [Related]  

  • 68. [Influenza in the winter of 1986-87; modification of influenza vaccine for the 1987-88 season].
    Masurel N; Beyer WE
    Ned Tijdschr Geneeskd; 1987 Nov; 131(47):2132-3. PubMed ID: 3683651
    [No Abstract]   [Full Text] [Related]  

  • 69. Epidemiological evaluation of the protection conferred by the Nivgrip vaccine against influenza caused by the A(H3N2) virus.
    Teodorovici G; Ivan A; Vieriu V; Duman F; Stenţer M; Frunzăreanu N; Petrescu A; Mihail A; Cajal N
    Virologie; 1984; 35(1):39-41. PubMed ID: 6710860
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Seasonality, timing, and climate drivers of influenza activity worldwide.
    Azziz Baumgartner E; Dao CN; Nasreen S; Bhuiyan MU; Mah-E-Muneer S; Al Mamun A; Sharker MA; Zaman RU; Cheng PY; Klimov AI; Widdowson MA; Uyeki TM; Luby SP; Mounts A; Bresee J
    J Infect Dis; 2012 Sep; 206(6):838-46. PubMed ID: 22829641
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Both hemispheric influenza vaccine recommendations would have missed near half of the circulating viruses in Madagascar.
    Guillebaud J; Héraud JM; Razanajatovo NH; Livinski AA; Alonso WJ
    Influenza Other Respir Viruses; 2017 Nov; 11(6):473-478. PubMed ID: 29067783
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The surveillance and facing new challenge of influenza].
    Guo Y; Tang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jan; 24(1):2-3. PubMed ID: 15470772
    [No Abstract]   [Full Text] [Related]  

  • 73. Exploring cross-protection between influenza strains by an epidemiological model.
    Lavenu A; Valleron AJ; Carrat F
    Virus Res; 2004 Jul; 103(1-2):101-5. PubMed ID: 15163497
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Seasonal influenza prevention and control in Taiwan-Strategies revisited.
    Su CP; Tsou TP; Chen CH; Lin TY; Chang SC; ;
    J Formos Med Assoc; 2019 Mar; 118(3):657-663. PubMed ID: 30648551
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidemiology and timing of seasonal influenza epidemics in the Asia-Pacific region, 2010-2017: implications for influenza vaccination programs.
    El Guerche-Séblain C; Caini S; Paget J; Vanhems P; Schellevis F
    BMC Public Health; 2019 Mar; 19(1):331. PubMed ID: 30898100
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimal control of vaccination dynamics during an influenza epidemic.
    Jaberi-Douraki M; Moghadas SM
    Math Biosci Eng; 2014 Oct; 11(5):1045-63. PubMed ID: 25347806
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Benefits and limitations of the Witwatersrand influenza and acute respiratory infections surveillance programme.
    Schoub BD; Johnson S; McAnerney J; Blackburn NK
    S Afr Med J; 1994 Oct; 84(10):674-8. PubMed ID: 7839255
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Influenza: Can we cope better with the unpredictable?
    Dos Santos G; Neumeier E; Bekkat-Berkani R
    Hum Vaccin Immunother; 2016 Mar; 12(3):699-708. PubMed ID: 26360135
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Which influenza vaccine formulation should be used in Kenya? A comparison of influenza isolates from Kenya to vaccine strains, 2007-2013.
    Waiboci LW; Mott JA; Kikwai G; Arunga G; Xu X; Mayieka L; Emukule GO; Muthoka P; Njenga MK; Fields BS; Katz MA
    Vaccine; 2016 May; 34(23):2593-601. PubMed ID: 27079931
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The evolution of seasonal influenza viruses.
    Petrova VN; Russell CA
    Nat Rev Microbiol; 2018 Jan; 16(1):47-60. PubMed ID: 29081496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.